حدد سهمًا أو عملة مشفرة في شريط البحث للحصول على ملخص
JCR Pharmaceuticals Co Ltd
4552JCR Pharmaceuticals Co., Ltd., together with its subsidiaries, engages in the research, development, manufacture, import and export, and sale of pharmaceutical products, regenerative medicines, and drug substances in Japan. It offers various therapeutic products, including GROWJECT used for the treatment of growth hormone deficiency and short stature; IZCARGO to treat Mucopolysaccharidosis type II; Agalsidase Beta BS I.V. Infusion used for the treatment of Fabry disease; and TEMCELL HS Inj used to treat acute graft-versus-host disease. The company develops Epoetin Alfa BS and Darbepoetin Alfa BS Injections for the treatment of renal anemia. In addition, it sells, imports, and exports medical devices and laboratory instruments; and purchases and sells medical and research equipment. The company has a collaboration agreement with Angelini Pharma for the development of novel biologic therapies; and a. joint research agreement with Modalis Therapeutics Corporation to evaluate the drug delivery technology of the gene therapy to the central nervous system (CNS) assuming CNS diseases as a target. JCR Pharmaceuticals Co., Ltd. was incorporated in 1975 and is headquartered in Ashiya, Japan. Address: 3-19 Kasuga-cho, Ashiya, Japan, 659-0021
Analytics
سعر الهدف في وول ستريت
135 931.93 JPYنسبة السعر إلى الأرباح
–العائد الربحي
3.05 %السنة الحالية
العام الماضي
الربع الحالي
الربع الأخير
السنة الحالية
العام الماضي
الربع الحالي
الربع الأخير
الشخصيات الرئيسية 4552
تحليلات الأرباح 4552
نمو الأرباح على مدى 5 سنوات
196 %النمو المستمر
2 سنينمعدل الدفع 5 سنوات في المتوسط
43 %تاريخ الأرباح 4552
تقييم الأسهم 4552
المالية 4552
نتائج | 2019 | ديناميات |